Literature DB >> 26846833

Clinical phenotypes in adult patients with bronchiectasis.

Stefano Aliberti1, Sara Lonni2, Simone Dore3, Melissa J McDonnell4, Pieter C Goeminne5, Katerina Dimakou6, Thomas C Fardon7, Robert Rutherford4, Alberto Pesci2, Marcos I Restrepo8, Giovanni Sotgiu3, James D Chalmers7.   

Abstract

Bronchiectasis is a heterogeneous disease. This study aimed at identifying discrete groups of patients with different clinical and biological characteristics and long-term outcomes.This was a secondary analysis of five European databases of prospectively enrolled adult outpatients with bronchiectasis. Principal component and cluster analyses were performed using demographics, comorbidities, and clinical, radiological, functional and microbiological variables collected during the stable state. Exacerbations, hospitalisations and mortality during a 3-year follow-up were recorded. Clusters were externally validated in an independent cohort of patients with bronchiectasis, also investigating inflammatory markers in sputum.Among 1145 patients (median age 66 years; 40% male), four clusters were identified driven by the presence of chronic infection with Pseudomonas aeruginosaor other pathogens and daily sputum: "Pseudomonas" (16%), "Other chronic infection" (24%), "Daily sputum" (33%) and "Dry bronchiectasis" (27%). Patients in the four clusters showed significant differences in terms of quality of life, exacerbations, hospitalisations and mortality during follow-up. In the validation cohort, free neutrophil elastase activity, myeloperoxidase activity and interleukin-1β levels in sputum were significantly different among the clusters.Identification of four clinical phenotypes in bronchiectasis could favour focused treatments in future interventional studies designed to alter the natural history of the disease.
Copyright ©ERS 2016.

Entities:  

Mesh:

Year:  2016        PMID: 26846833     DOI: 10.1183/13993003.01899-2015

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  61 in total

Review 1.  Advances in bronchiectasis: endotyping, genetics, microbiome, and disease heterogeneity.

Authors:  Patrick A Flume; James D Chalmers; Kenneth N Olivier
Journal:  Lancet       Date:  2018-09-08       Impact factor: 79.321

2.  Pharmacotherapy for Non-Cystic Fibrosis Bronchiectasis: Results From an NTM Info & Research Patient Survey and the Bronchiectasis and NTM Research Registry.

Authors:  Emily Henkle; Timothy R Aksamit; Alan F Barker; Jeffrey R Curtis; Charles L Daley; M Leigh Anne Daniels; Angela DiMango; Edward Eden; Kevin Fennelly; David E Griffith; Margaret Johnson; Michael R Knowles; Amy Leitman; Philip Leitman; Elisha Malanga; Mark L Metersky; Peadar G Noone; Anne E O'Donnell; Kenneth N Olivier; Delia Prieto; Matthias Salathe; Byron Thomashow; Gregory Tino; Gerard Turino; Susan Wisclenny; Kevin L Winthrop
Journal:  Chest       Date:  2017-05-05       Impact factor: 9.410

3.  Integrative microbiomics in bronchiectasis exacerbations.

Authors:  Micheál Mac Aogáin; Jayanth Kumar Narayana; Pei Yee Tiew; Nur A'tikah Binte Mohamed Ali; Valerie Fei Lee Yong; Tavleen Kaur Jaggi; Albert Yick Hou Lim; Holly R Keir; Alison J Dicker; Kai Xian Thng; Akina Tsang; Fransiskus Xaverius Ivan; Mau Ern Poh; Martina Oriano; Stefano Aliberti; Francesco Blasi; Teck Boon Low; Thun How Ong; Brian Oliver; Yan Hui Giam; Augustine Tee; Mariko Siyue Koh; John Arputhan Abisheganaden; Krasimira Tsaneva-Atanasova; James D Chalmers; Sanjay H Chotirmall
Journal:  Nat Med       Date:  2021-04-05       Impact factor: 53.440

Review 4.  Year in review 2016: Respiratory infections, acute respiratory distress syndrome, pleural diseases, lung cancer and interventional pulmonology.

Authors:  Marcos I Restrepo; James D Chalmers; Yuanlin Song; Christopher Mallow; Justin Hewlett; Fabien Maldonado; Lonny Yarmus
Journal:  Respirology       Date:  2017-02-28       Impact factor: 6.424

Review 5.  [Pseudomonas aeruginosa infections in chronic obstructive pulmonary disease : Role of long-term antibiotic treatment].

Authors:  G G U Rohde; T Welte
Journal:  Internist (Berl)       Date:  2017-11       Impact factor: 0.743

6.  The Clinical Features of Bronchiectasis Associated with Alpha-1 Antitrypsin Deficiency, Common Variable Immunodeficiency and Primary Ciliary Dyskinesia--Results from the U.S. Bronchiectasis Research Registry.

Authors:  Edward Eden; Radmila Choate; Alan Barker; Doreen Addrizzo-Harris; Timothy R Aksamit; Charles L Daley; M Leigh Anne Daniels; Angela DiMango; Kevin Fennelly; David E Griffith; Margaret M Johnson; Michael R Knowles; Mark L Metersky; Peadar G Noone; Anne E O'Donnell; Kenneth N Olivier; Matthias A Salathe; Andreas Schmid; Byron Thomashow; Gregory Tino; Gerard M Turino; Kevin L Winthrop
Journal:  Chronic Obstr Pulm Dis       Date:  2019-04-09

7.  Duration of antibiotic therapy in non-cystic fibrosis bronchiectasis.

Authors:  R Somayaji; C H Goss
Journal:  Curr Pulmonol Rep       Date:  2019-11-26

Review 8.  The clinical phenotype of bronchiectasis and its clinical guiding implications.

Authors:  Li Gao; Ke-Ru Qin; Ting Li; Hai-Long Wang; Min Pang
Journal:  Exp Biol Med (Maywood)       Date:  2020-11-26

9.  Neutrophil Elastase Activity Is Associated with Exacerbations and Lung Function Decline in Bronchiectasis.

Authors:  James D Chalmers; Kelly L Moffitt; Guillermo Suarez-Cuartin; Oriol Sibila; Simon Finch; Elizabeth Furrie; Alison Dicker; Karolina Wrobel; J Stuart Elborn; Brian Walker; S Lorraine Martin; Sara E Marshall; Jeffrey T-J Huang; Thomas C Fardon
Journal:  Am J Respir Crit Care Med       Date:  2017-05-15       Impact factor: 21.405

Review 10.  Protease-Antiprotease Imbalance in Bronchiectasis.

Authors:  Martina Oriano; Francesco Amati; Andrea Gramegna; Anthony De Soyza; Marco Mantero; Oriol Sibila; Sanjay H Chotirmall; Antonio Voza; Paola Marchisio; Francesco Blasi; Stefano Aliberti
Journal:  Int J Mol Sci       Date:  2021-06-01       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.